Open AccessBrief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma
Author(s) -
J Torgersen,
Michael J. Kallan,
Dena M. Carbonari,
Lesley S. Park,
Rajni Mehta,
Kathryn D’Addeo,
Janet P. Tate,
Joseph K. Lim,
Matthew Bidwell Goetz,
Maria C. RodriguezBarradas,
Norbert Bräu,
Sheldon T. Brown,
Tamar H. Taddei,
Amy C. Justice,
Vincent Lo Re
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002510
Subject(s) - cirrhosis , medicine , hepatocellular carcinoma , receiver operating characteristic , confidence interval , gastroenterology , cohort , oncology
Hepatocellular carcinoma (HCC) may develop in the absence of cirrhosis in HIV, and determining how often this occurs can provide insights into mechanisms of carcinogenesis. Studies evaluating the prevalence of cirrhosis in the setting of HCC among people living with HIV (PLWH) often rely on noninvasive markers, such as the Fibrosis-4 Index for Hepatic Fibrosis (FIB-4). However, the accuracy of FIB-4 for cirrhosis in the setting of HCC has not been determined among PLWH.